Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01654965 · ClinicalTrials.gov registry record · Phase 1
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01654965: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01654965 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01654965, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of tivantinib and topotecan hydrochloride in treating patients with advanced or metastatic solid tumors. Tivantinib and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Pegfilgrastim
- OTHER Pharmacological Study
- DRUG Topotecan Hydrochloride
- DRUG Tivantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-07-24 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01654965
The ClinicalTrials.gov registry entry for NCT01654965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01654965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01654965 about?
NCT01654965 is a clinical study titled "Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors". This phase I trial studies the side effects and best dose of tivantinib and topotecan hydrochloride in treating patients with advanced or metastatic solid tumors. Tivantinib and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01654965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2012-07-24. Estimated completion is 2018-03-29.
What interventions are being tested in trial NCT01654965?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pegfilgrastim (BIOLOGICAL), Pharmacological Study (OTHER), Topotecan Hydrochloride (DRUG), Tivantinib (DRUG).
Who is sponsoring clinical trial NCT01654965?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.